Frontline Management of CLL in 2021
Author:
Affiliation:
1. University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, CA
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Oncology (nursing),Health Policy,Oncology
Link
https://ascopubs.org/doi/pdfdirect/10.1200/OP.21.00258
Reference24 articles.
1. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
2. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
3. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
4. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting;JCO Oncology Practice;2024-08
2. Real‐world comparative effectiveness of venetoclax‐obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia;British Journal of Haematology;2024-07-24
3. Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL);Clinical Lymphoma Myeloma and Leukemia;2024-02
4. Bowel, lung, and retinal ischemia: Rare manifestations of leukostasis syndrome in a man with chronic lymphocytic leukemia—A case report and review of the literature;Current Problems in Cancer: Case Reports;2023-09
5. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia;Applied Health Economics and Health Policy;2023-08-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3